Interleukin-13 inhibition by tralokinumab reduces inducible T-cell costimulator-positive innate lymphoid cells in skin lesions of atopic dermatitis
Interleukin-13 inhibition by tralokinumab reduces inducible T-cell costimulator-positive innate lymphoid cells in skin lesions of atopic dermatitis
复制标题
tralokinumab 抑制 Interleukin-13 可减少特应性皮炎皮损中诱导型 T 细胞共刺激物阳性先天淋巴细胞
DOI：
10.1093/bjd/ljac008
复制
发表时间：
2023
影响因子：
10.3
通讯作者：
Kabashima Kenji
中科院分区：
文献类型：
--
作者：
Kogame Toshiaki;Yonekura Satoru;Lovato Paola;Hirata Masahiro;Takimoto-ito Riko;Takegami Tomoya;Komatsu-Fujii Takayoshi;Kambe Naotomo;Nomura Takashi;R?pke Mads A;Kabashima Kenji
尽管本研究中皮肤ILC的频率较低且分析的样本数量有限，但我们的数据表明，ICOS+ ILC表达IL-13 R α1，并且在曲洛克木单抗治疗开始后4周，ICOS+ ILC的密度降低。
Despite the low frequency of skin ILCs and the limited number of samples analyzed in this study, our data indicate that ICOS+ ILCs express IL-13Rα1 and that the density of ICOS+ ILCs decreased four weeks after initiation of treatment with tralokinumab.